Sign in Subscribe
Genetic research

Metformin's Effect on Squamous Cell Carcinoma Questioned in New Research

Strategic Insights

— 1 min read

Recent research has investigated the potential of metformin, a medication commonly used to treat type 2 diabetes, as a radiosensitizer for squamous cell carcinoma. The study, conducted by researchers from the University of Zurich, Bern University Hospital, and other institutions, aimed to determine whether metformin could reduce tumor hypoxia in patients with oral cavity squamous cell carcinoma (OCSCC). The study involved 25 non-diabetic patients, who received preoperative metformin for 10 to 14 days before surgery. The results showed that metformin did not significantly improve tumor hypoxia or alter gene expression associated with hypoxia in OCSCC.

Key Takeaways:

  • The study, led by Simon A. Mueller, investigated the effect of metformin on hypoxia-associated gene expression in OCSCC in non-diabetic patients.
  • The research involved 25 patients, 15 of whom completed the study protocol and passed quality checks.
  • The results showed that metformin did not significantly improve tumor hypoxia or alter gene expression associated with hypoxia in OCSCC after 10 to 14 days of treatment.
  • The researchers concluded that the study does not support the hypothesis that metformin improves tumor hypoxia in OCSCC.
  • The study was funded by the University of Zurich and has been peer-reviewed by European Archives of Oto-Rhino-Laryngology.
  • The research was conducted by a team of researchers from the University of Bern, Bern University Hospital, and other institutions.

Statistics:

  • 25 non-diabetic patients were enrolled in the study.
  • 15 patients completed the study protocol and passed quality checks.
  • Metformin was administered to patients for 10 to 14 days before surgery.
  • No significant difference in gene expression associated with hypoxia was observed after adjustment for multiple testing.
  • Gene expression profiling was performed using RNASeq, emphasizing on hypoxia-associated signaling pathways.

Sources:

  • European Archives of Oto-Rhino-Laryngology (2025)
  • Bern University Hospital Reports Findings in Squamous Cell Carcinoma (Effect of metformin on hypoxia-associated gene expression in oral cavity squamous cell carcinoma in non-diabetic patients - a prospective window of opportunity study)
  • NewsRx. Chemicals & Chemistry. June 20, 2025; p 249.
  • Springer. European Archives of Oto-Rhino-Laryngology. www.springer.com; European Archives of Oto-Rhino-Laryngology. www.springerlink.com/content/0937-4477/

Read more